Table 2.

Smoking Outcomes^a

	Varenicline (N = 45)	Placebo (N = 48)	OR	95% CI	P
Characteristics	n (%)	n (%)
End-of-treatment
Point prevalence abstinence	24 (53.3)	7 (14.5)	6.69	2.48–18.06	<.001
Gender-adjusted
Treatment			9.58	3.19–28.76	<.001
Female			3.20	1.09–9.44	.035
Prolonged abstinence	18 (40.0)	4 (8.3)	7.33	2.24–23.98	.001
Gender-adjusted
Treatment			8.82	2.56–30.30	<.001
Female			2.04	0.68–6.14	.206
6 months
Point prevalence abstinence	18 (40.0)	10 (20.8)	2.53	1.01–6.34	.047
Gender-adjusted
Treatment			3.57	1.31–9.71	.013
Female			3.70	1.27–10.79	.017
Prolonged abstinence	14 (31.1)	4 (8.3)	4.97	1.49–16.53	.009
Gender-adjusted
Treatment			6.61	1.87–23.38	.003
Gender			3.12	0.92–10.56	.067

CI = confidence interval; OR = odds ratio.

^aData were analyzed using logistic regression. Analyses were performed with no covariate adjustment and also with gender included as a covariate. Point prevalence was defined as CO-confirmed self-reported no tobacco use in the previous 7 days. Participants who met criteria for CO-confirmed 7-day point prevalence abstinence at weeks 12 and 26 were defined as meeting criteria for prolonged abstinence if they submitted negative responses to both of the following questions: “Since 14 days after your target quit date, have you used any tobacco on each of 7 consecutive days?” and “Since 14 days after your target quit date, have you used any tobacco on at least one day in each of 2 consecutive weeks?”